IRadimed IRMD
$81.02 −$0.24 (-0.30%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $81.02 0.00%
Open$80.61
Prev close$81.26
Day range$80.61 – $82.11
Volume101.3K
Market cap$1.04B
P/E (TTM)43.3
Dividend yield0.95%
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$24.20M+14.2% YoY
Operating profit$8.14M+19.1% YoY
Net profit$6.51M+16.7% YoY
Diluted EPS$0.51+18.6% YoY
Free cash flow$6.79M+18.6% YoY
Operating cash flow$7.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin75.5%
Operating margin32.3%
Net margin26.8%
Return on equity23.4%
Return on assets20.3%
Return on invested capital23.4%
Current ratio8.99
Liabilities / assets12.1%
Cash & investments$63.29M
Net cash (debt)$63.29M
Free cash flow / sales28.7%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $24.20M | $20.47M | $21.98M | $83.81M | $22.69M |
| Total Operating Revenue | $24.20M | $20.47M | $21.98M | $83.81M | $22.69M |
| Cost of Revenue | $5.75M | $5.31M | $5.17M | $19.49M | $5.66M |
| Gross Profit | $18.46M | $15.16M | $16.81M | $64.32M | $17.03M |
| Operating Expense | $10.32M | $8.77M | $9.58M | $38.18M | $9.94M |
| Selling and Admin Expenses | $9.44M | $8.11M | $8.62M | $35.20M | $9.14M |
| -Selling & Marketing Expense | $4.91M | $4.25M | $4.05M | $17.42M | $4.60M |
| -General & Admin Expense | $4.53M | $3.87M | $4.57M | $17.78M | $4.54M |
| Research & Development | $875,000.00 | $657,000.00 | $956,000.00 | $2.98M | $799,000.00 |
| Operating Profit | $8.14M | $6.39M | $7.24M | $26.15M | $7.09M |
| Other Income (Expense) | $529,000.00 | $497,000.00 | $532,000.00 | $205,000.00 | -$1.31M |
| Other Non-Operating Income (Expenses) | $529,000.00 | $497,000.00 | $532,000.00 | – | – |
| Pretax Profit | $8.67M | $6.89M | $7.77M | $28.36M | $7.79M |
| Tax | $2.16M | $1.67M | $1.95M | $5.88M | $1.35M |
| Net Profit | $6.51M | $5.22M | $5.82M | $22.48M | $6.44M |
| Profit from Continuing Operations | $6.51M | $5.22M | $5.82M | $22.48M | $6.44M |
| Net Income to Parent Company | $6.51M | $5.22M | $5.82M | $22.48M | $6.44M |
| Net Income to Common Stockholders | $6.51M | $5.22M | $5.82M | $22.48M | $6.44M |
| Basic EPS | $0.51 | $0.41 | $0.46 | $1.77 | $0.51 |
| Diluted EPS | $0.51 | $0.41 | $0.45 | $1.75 | $0.50 |
| Dividend Per Share | $0.20 | $0.20 | $0.20 | $0.68 | $0.17 |
| Net Non-Operating Interest Income (Expense) | – | – | – | $2.01M | – |
| Non-Operating Interest Income | – | – | – | $2.01M | – |
| Gain on Sale of Security | – | – | – | $2,000.00 | – |
| Special Income (Charges) | – | – | – | $203,000.00 | – |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | $203,000.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $121.07M | $114.98M | $114.39M | $108.78M | $108.78M |
| Total Current Assets | $92.80M | $86.72M | $86.42M | $81.20M | $81.20M |
| Cash and Cash Equivalents & Short-Term Investments | $63.29M | $59.08M | $56.37M | $51.16M | $51.16M |
| -Cash and Cash Equivalents | $63.29M | $59.08M | $56.37M | $51.16M | $51.16M |
| Receivables | $13.67M | $13.19M | $13.42M | $13.67M | $13.67M |
| -Accounts Receivable | $13.67M | $13.19M | $13.42M | $13.67M | $13.67M |
| Prepaid Assets | $1.10M | $792,000.00 | $3.13M | – | – |
| Inventory | $13.49M | $12.26M | $11.88M | $11.62M | $11.62M |
| Other Current Assets | $1.25M | $1.40M | $1.63M | $4.76M | $4.76M |
| Total Non-Current Assets | $28.27M | $28.25M | $27.97M | $27.57M | $27.57M |
| Net PPE | $24.08M | $24.21M | $24.23M | $23.86M | $23.86M |
| -Gross PPE | $30.05M | $29.88M | $29.59M | $28.93M | $28.93M |
| -Accumulated Depreciation | -$5.97M | -$5.67M | -$5.36M | -$5.07M | -$5.07M |
| Goodwill and Other Intangible Assets | $3.41M | $3.44M | $3.29M | $3.38M | $3.38M |
| -Other Intangible Assets | $3.41M | $3.44M | $3.29M | $3.38M | $3.38M |
| Non-Current Deferred Assets | $524,000.00 | $363,000.00 | $231,000.00 | $94,000.00 | $94,000.00 |
| Other Non-Current Assets | $258,000.00 | $244,000.00 | $225,000.00 | $239,000.00 | $239,000.00 |
| Total Liabilities | $14.62M | $13.23M | $15.88M | $14.16M | $14.16M |
| Total Current Liabilities | $10.32M | $9.16M | $12.12M | $10.18M | $10.18M |
| Payables | $2.97M | $2.49M | $6.51M | $3.63M | $3.63M |
| -Accounts Payable | $2.42M | $1.85M | $2.18M | $1.82M | $1.82M |
| -Total Tax Payable | $548,000.00 | $641,000.00 | $4.33M | $1.81M | $1.81M |
| Current Accrued Expenses | $3.62M | $3.06M | $2.07M | $3.22M | $3.22M |
| Current Provisions | $161,000.00 | $146,000.00 | $144,000.00 | $144,000.00 | $144,000.00 |
| Current Deferred Liabilities | $3.57M | $3.47M | $3.40M | $2.87M | $2.87M |
| Total Non-Current Liabilities | $4.29M | $4.06M | $3.76M | $3.98M | $3.98M |
| Non-Current Deferred Liabilities | $4.29M | $4.06M | $3.76M | $3.98M | $3.98M |
| Total Equity | $106.45M | $101.75M | $98.51M | $94.62M | $94.62M |
| Stockholders' Equity | $106.45M | $101.75M | $98.51M | $94.62M | $94.62M |
| Capital Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Common Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| Additional Paid-In Capital | $32.35M | $31.59M | $31.02M | $30.39M | $30.39M |
| Retained Earnings | $74.10M | $70.15M | $67.49M | $64.23M | $64.23M |
| Other Current Liabilities | – | – | – | $313,000.00 | $313,000.00 |
| Long Term Debt and Capital Lease Obligation | – | – | – | $0.00 | $0.00 |
| -Long Term Capital Lease Obligation | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.00M | $5.94M | $8.29M | $24.95M | $5.92M |
| Net cash flow from continuing operations | $7.00M | $5.94M | $8.29M | $24.95M | $5.92M |
| Net Income from Continuing Operations | $6.51M | $5.22M | $5.82M | $22.48M | $6.44M |
| Depreciation & Depletion & Amortization | $412,000.00 | $410,000.00 | $455,000.00 | $1.17M | $381,000.00 |
| Deferred Tax | -$161,000.00 | -$132,000.00 | -$137,000.00 | $2.73M | $2.33M |
| Change in Working Capital | -$671,000.00 | -$344,000.00 | $1.42M | -$4.35M | -$3.95M |
| -Change in Receivables | -$593,000.00 | $280,000.00 | $212,000.00 | -$3.03M | $191,000.00 |
| -Change in Inventory | -$1.30M | -$515,000.00 | -$534,000.00 | -$1.38M | $54,000.00 |
| -Change in Prepaid Assets | -$158,000.00 | $2.56M | $7,000.00 | -$2.71M | -$1.96M |
| -Change in Payables and Accrued Expense | $1.04M | -$3.03M | $1.41M | $1.33M | -$2.34M |
| -Change in Other Current Assets | -$14,000.00 | -$18,000.00 | $13,000.00 | -$40,000.00 | -$25,000.00 |
| -Change in Other Current Liabilities | $0.00 | $0.00 | $0.00 | -$150,000.00 | $0.00 |
| -Change In Other Working Capital | $348,000.00 | $380,000.00 | $305,000.00 | $1.62M | $125,000.00 |
| Net cash flow from investing | -$212,000.00 | -$443,000.00 | -$469,000.00 | -$8.42M | -$416,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$212,000.00 | -$443,000.00 | -$469,000.00 | -$8.42M | -$416,000.00 |
| Capital Expenditure | -$82,000.00 | -$258,000.00 | -$66,000.00 | -$656,000.00 | -$122,000.00 |
| Net PPE Purchase and Sale | -$130,000.00 | -$185,000.00 | -$403,000.00 | -$7.77M | -$294,000.00 |
| Financing Cash Flow | -$2.58M | -$2.79M | -$2.61M | -$17.60M | -$10.87M |
| Net Cash Flow from Continuing Financing Activities | -$2.58M | -$2.79M | -$2.61M | -$17.60M | -$10.87M |
| Cash Dividends Paid | -$2.56M | -$2.56M | -$2.56M | -$15.04M | -$8.55M |
| Net Other Financing Charges | -$19,000.00 | -$234,000.00 | -$50,000.00 | -$2.56M | -$2.32M |
| Ending Cash Balance | $63.29M | $59.08M | $56.37M | $51.16M | $51.16M |
| Net Change in Cash | $4.21M | $2.71M | $5.22M | -$1.08M | -$5.37M |
| Beginning Cash Balance | $59.08M | $56.37M | $51.16M | $52.23M | $56.53M |
| Free Cash Flow | $6.79M | $5.50M | $7.82M | $16.53M | $5.51M |
| Gain/Loss from Continuing Operations | – | – | – | $37,000.00 | $3,000.00 |
| Proceeds from Stock Option Exercised | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on IRMD.
Sign in to join the discussion.